Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT00187122
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 27
- Registration Number
- NCT00169156
- Locations
- 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
🇫🇷Centre Henri Becquerel, Rouen, France
Treatment of Acute Lymphoblastic Leukemia in Children
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-04-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 498
- Registration Number
- NCT00165178
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165139
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 138
- Registration Number
- NCT00135499
- Locations
- 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 23
- Registration Number
- NCT00133991
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 240
- Registration Number
- NCT00131027
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.